mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2025-3-115-120mrj-1784Research ArticleОБЗОРЫREVIEWSЭффективность и безопасность применения ингибиторов кальциневрина у пациентов с системной красной волчанкойEfficacy and safety of calcineurin inhibitors use in patients with systemic lupus erythematosushttps://orcid.org/0000-0002-4160-7218НикишинаН. Ю.NikishinaN. Yu.

Нина Юрьевна Никишина 

115522, Москва, Каширское шоссе, 34А 

Nina Yuryevna Nikishina 

34A, Kashirskoye Shosse, Moscow, 115522 

lashinanina@gmail.comhttps://orcid.org/0000-0002-1663-7810АсееваЕ. А.AseevaE. A.

115522, Москва, Каширское шоссе, 34А 

34A, Kashirskoye Shosse, Moscow, 115522 

https://orcid.org/0000-0002-5206-1732СоловьевС. К.SolovievS. K.

115522, Москва, Каширское шоссе, 34А 

34A, Kashirskoye Shosse, Moscow, 115522 

https://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

115522, Москва, Каширское шоссе, 34А 

125993, Москва, ул. Баррикадная, 2/1, стр. 1 

34A, Kashirskoye Shosse, Moscow, 115522 

2/1, Barrikadnaya Street, Build. 1, 125993 Moscow 

https://orcid.org/0000-0003-3051-219XДацинаА. В.DatcinaA. V.

115522, Москва, Каширское шоссе, 34А 

34A, Kashirskoye Shosse, Moscow, 115522 

https://orcid.org/0009-0005-1269-5799ПлетнёвЕ. Т.PletnevE. T.

115522, Москва, Каширское шоссе, 34А 

34A, Kashirskoye Shosse, Moscow, 115522 

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» ; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology ; Department of Rheumatology, Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Federation202524062025193115120Copyright © Никишина Н.Ю., Асеева Е.А., Соловьев С.К., Лила А.М., Дацина А.В., Плетнёв Е.Т., 20252025Никишина Н.Ю., Асеева Е.А., Соловьев С.К., Лила А.М., Дацина А.В., Плетнёв Е.Т.Nikishina N.Y., Aseeva E.A., Soloviev S.K., Lila A.M., Datcina A.V., Pletnev E.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1784

Системная красная волчанка – сложное аутоиммунное заболевание, при котором более чем у трети пациентов возникает волчаночный нефрит (ВН), что приводит к развитию хронической болезни почек и терминальной стадии почечной недостаточности. Лечение ВН всегда было сложной задачей. Такролимус – эффективный иммунодепрессант, который в последние годы все чаще используется для лечения ВН.

Systemic lupus erythematosus is a complex autoimmune disease in which more than one-third of patients develop lupus nephritis (LN), leading to chronic kidney disease and end-stage renal failure. The treatment of LN has always been a challenge. Tacrolimus is an effective immunosuppressant that has been increasingly used in recent years for the treatment of LN.

системная красная волчанкаволчаночный нефритингибиторы кальциневринаsystemic lupus erythematosuslupus nephritiscalcineurin inhibitorsСтатья подготовлена в рамках научно-исследовательской работы (государственное задание № РК 125020501434-1).The article was prepared within the framework of a research project (State Assignment №PK 125020501434-1).ReferencesКозловская НЛ, Соловьев СК, Асеева ЕА и др. Обновленные рекомендации EULAR/ERA-EDTA 2019 г. по терапии волчаночного нефрита. Комментарии экспертов. Часть I. Современная ревматология, 2020;14(4):7-15. doi: 10.14412/1996-7012-2020-4-7-15.Kozlovskaya NL, Solov'ev SK, Aseeva EA, et al. The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part I. Sovremennaya revmatologiya = Modern Rheumatology Journal, 2020;14(4):7-15. (In Russ.). doi: 10.14412/1996-7012-2020-4-7-15.Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004 Feb;15(2):241-50. doi: 10.1097/01.asn.0000108969.21691.5d.Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004 Feb;15(2):241-50. doi: 10.1097/01.asn.0000108969.21691.5d.Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013 Aug;65(8):2154-60. doi: 10.1002/art.38006.Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013 Aug;65(8):2154-60. doi: 10.1002/art.38006.Yap DY, Tang CS, Ma MK, et al. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. 2012 Aug;27(8):3248-54. doi: 10.1093/ndt/gfs073.Yap DY, Tang CS, Ma MK, et al. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. 2012 Aug;27(8):3248-54. doi: 10.1093/ndt/gfs073.Doria A, Gatto M, Zen M, et al. Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun Rev. 2014 Jul;13(7):770-7. doi: 10.1016/j.autrev.2014.01.055. Epub 2014 Jan 27.Doria A, Gatto M, Zen M, et al. Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun Rev. 2014 Jul;13(7):770-7. doi: 10.1016/j.autrev.2014.01.055. Epub 2014 Jan 27.Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024 Jan 2; 83(1):15-29. doi: 10.1136/ard-2023-224762.Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024 Jan 2; 83(1):15-29. doi: 10.1136/ard-2023-224762.Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014 Jun; 73(6):958-67. doi: 10.1136/annrheumdis-2013-205139. Epub 2014 Apr 16.Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014 Jun; 73(6):958-67. doi: 10.1136/annrheumdis-2013-205139. Epub 2014 Apr 16.Engwenyu LR, Anderson AS. A Comprehensive Review of Calcineurin Inhibitors Used for Immunosuppression in Cardiac Transplantation. Handb Exp Pharmacol. 2022:272:27-38. doi: 10.1007/164_2021_549.Engwenyu LR, Anderson AS. A Comprehensive Review of Calcineurin Inhibitors Used for Immunosuppression in Cardiac Transplantation. Handb Exp Pharmacol. 2022:272:27-38. doi: 10.1007/164_2021_549.Safarini OA, Keshavamurthy C, Patel P. Calcineurin Inhibitors. 2023 Nov 12. In: StatPearls. Treasure Island: StatPearls Publishing; 2025.Safarini OA, Keshavamurthy C, Patel P. Calcineurin Inhibitors. 2023 Nov 12. In: StatPearls. Treasure Island: StatPearls Publishing; 2025.Pal A, Kaskel F. History of Nephrotic Syndrome and Evolution of its Treatment. Front Pediatr. 2016 May 30;4:56. doi: 10.3389/fped.2016.00056.Pal A, Kaskel F. History of Nephrotic Syndrome and Evolution of its Treatment. Front Pediatr. 2016 May 30;4:56. doi: 10.3389/fped.2016.00056.Руденко ЕВ, Томилина НА, Захарова ЕВ. Применение циклоспорина А для лечения нефротических типов хронических гломерулонефритов – болезни минимальных изменений и фокального сегментарного гломерулосклероза. Нефрология и диализ. 2015;17(2):156-172.Rudenko EV, Tomilina NA, Zakharova EV. The use of cyclosporine A for the treatment of neurotic types of chronic glomerulonephritis, a disease of minimal changes and focal segmental glomerulosclerosis. Nefrologiya i dializ. 2015;17(2):156-172. (In Russ.).Peleg Y, Bomback AS, Radhakrishnan J. The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis. Clin J Am Soc Nephrol. 2020 Jul 1;15(7):1066-1072. doi: 10.2215/CJN.13761119.Peleg Y, Bomback AS, Radhakrishnan J. The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis. Clin J Am Soc Nephrol. 2020 Jul 1;15(7):1066-1072. doi: 10.2215/CJN.13761119.Malakasioti G, Iancu D, Tullus K. Calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene mutations: a systematic review. Pediatr Nephrol. 2021 Jun;36(6):1353-1364. doi: 10.1007/s00467-020-04695-0.Malakasioti G, Iancu D, Tullus K. Calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene mutations: a systematic review. Pediatr Nephrol. 2021 Jun;36(6):1353-1364. doi: 10.1007/s00467-020-04695-0.Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009 Feb;4(2):481-508. doi: 10.2215/CJN.04800908.Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009 Feb;4(2):481-508. doi: 10.2215/CJN.04800908.Wu Q, Kuca K. Metabolic Pathway of Cyclosporine A and Its Correlation with Nephrotoxicity. Curr Drug Metab. 2019;20(2): 84-90. doi: 10.2174/1389200219666181031113505.Wu Q, Kuca K. Metabolic Pathway of Cyclosporine A and Its Correlation with Nephrotoxicity. Curr Drug Metab. 2019;20(2): 84-90. doi: 10.2174/1389200219666181031113505.Ong SC, Gaston RS. Thirty Years of Tacrolimus in Clinical Practice. Transplantation. 2021 Mar 1;105(3):484-495. doi: 10.1097/TP.0000000000003350.Ong SC, Gaston RS. Thirty Years of Tacrolimus in Clinical Practice. Transplantation. 2021 Mar 1;105(3):484-495. doi: 10.1097/TP.0000000000003350.Pallet N, Fernandez-Ramos AA, Loriot MA. Impact of Immunosuppressive Drugs on the Metabolism of T Cells. Int Rev Cell Mol Biol. 2018;341:169-200. doi: 10.1016/bs.ircmb.2018.05.009.Pallet N, Fernandez-Ramos AA, Loriot MA. Impact of Immunosuppressive Drugs on the Metabolism of T Cells. Int Rev Cell Mol Biol. 2018;341:169-200. doi: 10.1016/bs.ircmb.2018.05.009.Yoo WH, Lee SI, Kim TH, et al. Safety of Tacrolimus in Autoimmune Disease: Results From Post-marketing Surveillance in South Korea. J Rheum Dis. 2021 Oct 1;28(4): 202-215. doi: 10.4078/jrd.2021.28.4.202.Yoo WH, Lee SI, Kim TH, et al. Safety of Tacrolimus in Autoimmune Disease: Results From Post-marketing Surveillance in South Korea. J Rheum Dis. 2021 Oct 1;28(4): 202-215. doi: 10.4078/jrd.2021.28.4.202.Клим Ф. Такролимус при трансплантации почки. Сообщение I. Нефрология. 2007;11(2):7-25.Klim F. Tacrolimus during kidney transplantation. Message I. Nefrologiya. 2007;11(2):7- 25. (In Russ.).Arslansoyu Camlar S, Soylu A, Kavukcu S. Cyclosporine in Pediatric Nephrology. Iran J Kidney Dis. 2018 Nov;12(6):319-330.Arslansoyu Camlar S, Soylu A, Kavukcu S. Cyclosporine in Pediatric Nephrology. Iran J Kidney Dis. 2018 Nov;12(6):319-330.Liu F, Mao JH. Calcineurin inhibitors and nephrotoxicity in children. World J Pediatr. 2018 Apr;14(2):121-126. doi: 10.1007/s12519-018-0125-y.Liu F, Mao JH. Calcineurin inhibitors and nephrotoxicity in children. World J Pediatr. 2018 Apr;14(2):121-126. doi: 10.1007/s12519-018-0125-y.Mohamed ME, Saqr A, Staley C, et al. Pharmacomicrobiomics: Immunosuppressive Drugs and Microbiome Interactions in Transplantation. Transplantation. 2024 Sep 1;108(9): 1895-1910. doi: 10.1097/TP.0000000000004926.Mohamed ME, Saqr A, Staley C, et al. Pharmacomicrobiomics: Immunosuppressive Drugs and Microbiome Interactions in Transplantation. Transplantation. 2024 Sep 1;108(9): 1895-1910. doi: 10.1097/TP.0000000000004926.Birdwell KA, Decker BS, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015 Jul;98(1):19-24. doi: 10.1002/cpt.113. Epub 2015 Jun 3.Birdwell KA, Decker BS, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015 Jul;98(1):19-24. doi: 10.1002/cpt.113. Epub 2015 Jun 3.Chong KM, Jiang H, Lo EAG, et al. Therapeutic Drug Monitoring in Patients with Systemic Lupus Erythematosus: Utility and Gaps. J Clin Med. 2024 Jan 13;13(2):451. doi: 10.3390/jcm13020451.Chong KM, Jiang H, Lo EAG, et al. Therapeutic Drug Monitoring in Patients with Systemic Lupus Erythematosus: Utility and Gaps. J Clin Med. 2024 Jan 13;13(2):451. doi: 10.3390/jcm13020451.Zhou T, Zhang X, Lin W, Lin S. Multitarget Therapy: An Effective and Safe Therapeutic Regimen for Lupus Nephritis. J Pharm Pharm Sci. 2019;22(1):365-375. doi: 10.18433/jpps30526.Zhou T, Zhang X, Lin W, Lin S. Multitarget Therapy: An Effective and Safe Therapeutic Regimen for Lupus Nephritis. J Pharm Pharm Sci. 2019;22(1):365-375. doi: 10.18433/jpps30526.Terasaki M, Takahashi H, Sato R, et al. Successful Treatment With Multitarget Therapy of Mycophenolate Mofetil and Tacrolimus for Cyclophosphamide-Resistant Antineutrophil Cytoplasmic Antibody-Associated Pauci-Immune Glomerulonephritis Developed Independently of Systemic Lupus Erythematosus. J Clin Rheumatol. 2021 Mar 1; 27(2):e79-e80. doi: 10.1097/RHU.0000000000001255.Terasaki M, Takahashi H, Sato R, et al. Successful Treatment With Multitarget Therapy of Mycophenolate Mofetil and Tacrolimus for Cyclophosphamide-Resistant Antineutrophil Cytoplasmic Antibody-Associated Pauci-Immune Glomerulonephritis Developed Independently of Systemic Lupus Erythematosus. J Clin Rheumatol. 2021 Mar 1; 27(2):e79-e80. doi: 10.1097/RHU.0000000000001255.Zhang X, Liu P, Zhang Z. Analysis of the Clinical Effects of the Combination of Mycophenolate Mofetil with Either Tacrolimus or Cyclophosphamide. Clinics (Sao Paulo). 2020 Nov 11;75:e1820. doi: 10.6061/clinics/2020/e1820Zhang X, Liu P, Zhang Z. Analysis of the Clinical Effects of the Combination of Mycophenolate Mofetil with Either Tacrolimus or Cyclophosphamide. Clinics (Sao Paulo). 2020 Nov 11;75:e1820. doi: 10.6061/clinics/2020/e1820Watanabe H, Yamanaka R, Sada KE, et al. The efficacy of add-on tacrolimus for minor flare in patients with systemic lupus erythematosus: a retrospective study. Lupus. 2016 Jan;25(1):54-60. doi: 10.1177/0961203315600538.Watanabe H, Yamanaka R, Sada KE, et al. The efficacy of add-on tacrolimus for minor flare in patients with systemic lupus erythematosus: a retrospective study. Lupus. 2016 Jan;25(1):54-60. doi: 10.1177/0961203315600538.Squifflet JP, Backman L, Claesson K, et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation. 2001 Jul 15;72(1):63- 9. doi: 10.1097/00007890-200107150-00014.Squifflet JP, Backman L, Claesson K, et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation. 2001 Jul 15;72(1):63- 9. doi: 10.1097/00007890-200107150-00014.Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9): 1725. doi: 10.1002/art.1780400928.Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9): 1725. doi: 10.1002/art.1780400928.Zhang H, Liu Z, Zhou M, et al. Multitarget Therapy for Maintenance Treatment of Lupus Nephritis. J Am Soc Nephrol. 2017 Dec;28(12):3671-3678. doi: 10.1681/ASN.2017030263.Zhang H, Liu Z, Zhou M, et al. Multitarget Therapy for Maintenance Treatment of Lupus Nephritis. J Am Soc Nephrol. 2017 Dec;28(12):3671-3678. doi: 10.1681/ASN.2017030263.Han SS, Kim DH, Lee SM, et al. Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants. Kidney Res Clin Pract. 2012 Sep;31(3): 157-62. doi: 10.1016/j.krcp.2012.06.007.Han SS, Kim DH, Lee SM, et al. Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants. Kidney Res Clin Pract. 2012 Sep;31(3): 157-62. doi: 10.1016/j.krcp.2012.06.007.Takeuchi T, Wakasugi N, Hashida T, et al. Long-Term Safety and Effectiveness of Tacrolimus in Patients With Lupus Nephritis in Japan: 10-Year Analysis of the Real-World TRUST Study. J Rheumatol. 2024 Jun 1;51(6): 613-621. doi: 10.3899/jrheum.2023-0210.Takeuchi T, Wakasugi N, Hashida T, et al. Long-Term Safety and Effectiveness of Tacrolimus in Patients With Lupus Nephritis in Japan: 10-Year Analysis of the Real-World TRUST Study. J Rheumatol. 2024 Jun 1;51(6): 613-621. doi: 10.3899/jrheum.2023-0210.Takeuchi T, Wakasugi N, Uno S, Makino H. Long-term Safety and Effectiveness of Tacrolimus in Patients With Lupus Nephritis: 5-year Interim Postmarketing Surveillance Study in Japan (TRUST). J Rheumatol. 2021 Jan 1;48(1):74-81. doi: 10.3899/jrheum.191008.Takeuchi T, Wakasugi N, Uno S, Makino H. Long-term Safety and Effectiveness of Tacrolimus in Patients With Lupus Nephritis: 5-year Interim Postmarketing Surveillance Study in Japan (TRUST). J Rheumatol. 2021 Jan 1;48(1):74-81. doi: 10.3899/jrheum.191008.Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol. 2009;19(6): 606-15. doi: 10.1007/s10165-009-0218-5. Epub 2009 Aug 18.Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol. 2009;19(6): 606-15. doi: 10.1007/s10165-009-0218-5. Epub 2009 Aug 18.Li X, Ren H, Zhang Q, et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant. 2012 Apr;27(4):1467-72. doi: 10.1093/ndt/gfr484.Li X, Ren H, Zhang Q, et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant. 2012 Apr;27(4):1467-72. doi: 10.1093/ndt/gfr484.Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2016 Jan;75(1):30-6. doi: 10.1136/annrheumdis-2014-206456Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2016 Jan;75(1):30-6. doi: 10.1136/annrheumdis-2014-206456Kamanamool N, Ingsathit A, Rattanasiri S, et al. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial. Lupus. 2018 Apr;27(4):647-656. doi: 10.1177/0961203317739131.Kamanamool N, Ingsathit A, Rattanasiri S, et al. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial. Lupus. 2018 Apr;27(4):647-656. doi: 10.1177/0961203317739131.Kawazoe M, Nanki T. Comparison of efficacy of continuous mycophenolate mofetil with sequential cyclophosphamide and tacrolimus as maintenance therapy for lupus nephritis. Lupus. 2024 Apr;33(4):319-327. doi: 10.1177/09612033241228177.Kawazoe M, Nanki T. Comparison of efficacy of continuous mycophenolate mofetil with sequential cyclophosphamide and tacrolimus as maintenance therapy for lupus nephritis. Lupus. 2024 Apr;33(4):319-327. doi: 10.1177/09612033241228177.Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024 Jan;105(1S): S1-S69. doi: 10.1016/j.kint.2023.09.002.Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024 Jan;105(1S): S1-S69. doi: 10.1016/j.kint.2023.09.002.Бобкова ИН, Буланов НМ, Захарова ЕВ и др. Клинические практические рекомендации KDIGO 2021 по лечению гломерулярных болезней. Нефрология и диализ. 2022;24(4):577-874. [Bobkova IN, Bulanov NM, Zakharova EV, et al. KDIGO 2021 Clinical Practice guidelines for the treatment of glomerular diseases. Nefrologiya i dializ. 2022;24(4):577-874. (In Russ.).Malakasioti G, Iancu D, Tullus K. Calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene mutations: a systematic review. Pediatr Nephrol. 2021 Jun; 36(6):1353-1364. doi: 10.1007/s00467-020-04695-0.Malakasioti G, Iancu D, Tullus K. Calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene mutations: a systematic review. Pediatr Nephrol. 2021 Jun; 36(6):1353-1364. doi: 10.1007/s00467-020-04695-0.Sun S, Zhang X, Guo Q, et al. Effect of tacrolimus with mycophenolate mofetil or cyclophosphamide on the renal response in systemic lupus erythematosus patients. BMC Rheumatol. 2024 Dec 18;8(1):68. doi: 10.1186/s41927-024-00439-x.Sun S, Zhang X, Guo Q, et al. Effect of tacrolimus with mycophenolate mofetil or cyclophosphamide on the renal response in systemic lupus erythematosus patients. BMC Rheumatol. 2024 Dec 18;8(1):68. doi: 10.1186/s41927-024-00439-x.Sakai R, Kurasawa T, Nishi E, et al. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, singlecentre, open label pilot study in Japan. Lupus. 2018 Feb;27(2):273-282. doi: 10.1177/0961203317719148.Sakai R, Kurasawa T, Nishi E, et al. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, singlecentre, open label pilot study in Japan. Lupus. 2018 Feb;27(2):273-282. doi: 10.1177/0961203317719148.Saad AF, Pacheco LD, Saade GR. Immunosuppressant Medications in Pregnancy. Obstet Gynecol. 2024 Apr 1;143(4):e94-e106. doi: 10.1097/AOG.0000000000005512.Saad AF, Pacheco LD, Saade GR. Immunosuppressant Medications in Pregnancy. Obstet Gynecol. 2024 Apr 1;143(4):e94-e106. doi: 10.1097/AOG.0000000000005512.Wiles K, Chappell L, Clark K, et al. Clinical practice guideline on pregnancy and renal disease. BMC Nephrol. 2019 Oct 31;20(1):401. doi: 10.1186/s12882-019-1560-2.Wiles K, Chappell L, Clark K, et al. Clinical practice guideline on pregnancy and renal disease. BMC Nephrol. 2019 Oct 31;20(1):401. doi: 10.1186/s12882-019-1560-2.Vasi I, Yildirim D, Karda RC, et al. Calcineurin inhibitors in unplanned pregnancies with active lupus disease: A retrospective observational study. Int J Clin Pharmacol Ther. 2024 Jul;62(7):326-333. doi: 10.5414/CP204528.Vasi I, Yildirim D, Karda RC, et al. Calcineurin inhibitors in unplanned pregnancies with active lupus disease: A retrospective observational study. Int J Clin Pharmacol Ther. 2024 Jul;62(7):326-333. doi: 10.5414/CP204528.

The authors declare that there are no conflicts of interest present.